CW October 2000
Volume 9Issue Number 10 October 2000 ISSN 10593802 V-Echinocandin Shows Promise Against Esophageal CandidiasisResults from a recent clinical trial, presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy held in Toronto, Ontario, September 17-20, 2000, indicate that V-Echinocardin (VEC), the first of a new class of antifungal agents known as the echinocandins, has great promise in the treatment of esophageal candidiasis.
Go to Previous Page Go to Next Page Source & Additional Reading R. J. White et al., 40th Interscience Conference on Antimicrobial Agents and Chemotherapy held in Toronto, Ontario, September 17-20, 2000. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW October 2000Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
